Siemens 2011 Annual Report Download - page 325

153 D. Consolidated Financial Statements 273 E. Additional information
158 D. Consolidated Statements of Changes in Equity
160 D. Notes to Consolidated Financial Statements
266 D. Supervisory Board and Managing Board
154 D. Consolidated Statements of Income
155 D.2 Consolidated Statements of Comprehensive Income
156 D. Consolidated Statements of Financial Position
157 D. Consolidated Statements of Cash Flow

merous information requests and inquiries were made on-site
by the authorities regarding tenders in the public healthcare
sector. OOO Siemens Russia is cooperating in the ongoing in-
vestigations which also relate to certain individual employees.
In April , the Defense Criminal Investigative Service of
the U.S. Department of Defense conducted a search at the
premises of Siemens Medical Solutions USA, Inc. in Malvern,
Pennsylvania, in connection with an investigation relating to
a Siemens contract with the U.S. Department of Defense for
the provision of medical equipment.
As previously reported, in June , Siemens AG and two
of its subsidiaries voluntarily self-reported, among others,
possible violations of U.S. Export Administration Regula-
tions to the responsible U.S. authorities. On October , ,
the U.S. Department of Commerce notified Siemens that it
closed its case without taking further action. On October ,
, the U.S. Department of the Treasury notified Siemens
that it opened an investigation. Siemens is cooperating with
the authorities.
As previously reported, since July  the EU Anti-Fraud Of-
fice OLAF, its Romanian equivalent DELAF and the Romanian
public prosecutor DNA have been investigating allegations of
fraud in connection with the  award of a contract to
FORTE Business Services (later Siemens IT Solutions and Ser-
vices Romania) to modernize the IT infrastructure of the Ro-
manian judiciary. On September , , OLAF put the matter
on monitoring status and decided not to open formal proceed-
ings. DELAF referred the matter to DNA and closed its investi-
gations. The DNA investigation is still ongoing. Siemens is co-
operating with the authorities.
For certain legal proceedings information required under IAS
, Provisions, Contingent Liabilities and Contingent Assets, is
not disclosed, if the Company concludes that the disclosure
can be expected to seriously prejudice the outcome of the liti-
gation.
In addition to the investigations and legal proceedings de-
scribed above, Siemens AG and its subsidiaries have been
named as defendants in various other legal actions and pro-
ceedings arising in connection with their activities as a global
diversified group. Some of these pending proceedings have
been previously disclosed. Some of the legal actions include
claims or potential claims for punitive damages or claims for
indeterminate amounts of damages. Siemens is from time to
time also involved in regulatory investigations beyond those
described above. Siemens is cooperating with the relevant au-
thorities in several jurisdictions and, where appropriate, con-
ducts internal investigations regarding potential wrongdoing
with the assistance of in-house and external counsel. Given
the number of legal actions and other proceedings to which
Siemens is subject, some may result in adverse decisions.
Siemens contests actions and proceedings when it considers
it appropriate. In view of the inherent difficulty of predicting
the outcome of such matters, particularly in cases in which
claimants seek indeterminate damages, Siemens may not be
able to predict what the eventual loss or range of loss related
to such matters will be. The final resolution of the matters dis-
cussed in this paragraph could have a material effect on
Siemens’ business, results of operations and financial condi-
tion for any reporting period in which an adverse decision is
rendered. However, Siemens currently does not expect its
business, results of operations and financial condition to be
materially affected by the additional legal matters not sepa-
rately discussed in this paragraph.
 – Additional disclosures
on financial instruments
The following table presents the carrying amounts of each
category of financial assets and financial liabilities:
September ,
(in millions of €)  
Financial assets:
Loans and receivables 25,865 24,749
Cash and cash equivalents 12,468 14,108
Derivatives designated
in a hedge accounting relationship 1,707 2,232
Financial assets held for trading 1,315 1,410
Available-for-sale financial assets 1,191 732
42,546 43,231
Financial liabilities:
Financial liabilities measured
at amortized cost 27,083 28,922
Financial liabilities held for trading 1,350 1,098
Derivatives designated
in a hedge accounting relationship 255 164
28,688 30,184